184 related articles for article (PubMed ID: 19459791)
1. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy.
Brestrich G; Zwinger S; Fischer A; Schmück M; Röhmhild A; Hammer MH; Kurtz A; Uharek L; Knosalla C; Lehmkuhl H; Volk HD; Reinke P
Am J Transplant; 2009 Jul; 9(7):1679-84. PubMed ID: 19459791
[TBL] [Abstract][Full Text] [Related]
2. Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial.
Smith C; Beagley L; Rehan S; Neller MA; Crooks P; Solomon M; Holmes-Liew CL; Holmes M; McKenzie SC; Hopkins P; Campbell S; Francis RS; Chambers DC; Khanna R
Clin Infect Dis; 2019 Feb; 68(4):632-640. PubMed ID: 29982441
[TBL] [Abstract][Full Text] [Related]
3. Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?
García-Ríos E; Nuévalos M; Mancebo FJ; Pérez-Romero P
Front Immunol; 2021; 12():657144. PubMed ID: 33968058
[TBL] [Abstract][Full Text] [Related]
4. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
5. Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient.
Macesic N; Langsford D; Nicholls K; Hughes P; Gottlieb DJ; Clancy L; Blyth E; Micklethwaite K; Withers B; Majumdar S; Fleming S; Sasadeusz J
Am J Transplant; 2015 Mar; 15(3):827-32. PubMed ID: 25648555
[TBL] [Abstract][Full Text] [Related]
6. Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy.
Brestrich G; Zwinger S; Roemhild A; Noutsias M; Rohde M; Keeren K; Sawitzki B; Volk HD; Reinke P; Hammer MH
J Immunother; 2009; 32(9):932-40. PubMed ID: 19816188
[TBL] [Abstract][Full Text] [Related]
7. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients.
Amini L; Vollmer T; Wendering DJ; Jurisch A; Landwehr-Kenzel S; Otto NM; Jürchott K; Volk HD; Reinke P; Schmueck-Henneresse M
Front Immunol; 2019; 10():1148. PubMed ID: 31191530
[TBL] [Abstract][Full Text] [Related]
9. Successful immunotherapy of HCMV disease using virus-specific T cells expanded from an allogeneic stem cell transplant recipient.
Hill GR; Tey SK; Beagley L; Crough T; Morton JA; Clouston AD; Whiting P; Khanna R
Am J Transplant; 2010 Jan; 10(1):173-9. PubMed ID: 19919660
[TBL] [Abstract][Full Text] [Related]
10. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.
Einsele H; Roosnek E; Rufer N; Sinzger C; Riegler S; Löffler J; Grigoleit U; Moris A; Rammensee HG; Kanz L; Kleihauer A; Frank F; Jahn G; Hebart H
Blood; 2002 Jun; 99(11):3916-22. PubMed ID: 12010789
[TBL] [Abstract][Full Text] [Related]
11. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.
Peggs KS; Verfuerth S; Pizzey A; Khan N; Guiver M; Moss PA; Mackinnon S
Lancet; 2003 Oct; 362(9393):1375-7. PubMed ID: 14585640
[TBL] [Abstract][Full Text] [Related]
12. Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.
Hakki M
Curr Hematol Malig Rep; 2020 Apr; 15(2):90-102. PubMed ID: 31981100
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution.
Clancy LE; Blyth E; Simms RM; Micklethwaite KP; Ma CK; Burgess JS; Antonenas V; Shaw PJ; Gottlieb DJ
Biol Blood Marrow Transplant; 2013 May; 19(5):725-34. PubMed ID: 23380344
[TBL] [Abstract][Full Text] [Related]
14. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.
Iwasenko JM; Scott GM; Naing Z; Glanville AR; Rawlinson WD
Transpl Infect Dis; 2011 Apr; 13(2):145-53. PubMed ID: 21070537
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
Boivin G; Goyette N; Gilbert C; Humar A; Covington E
Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.
Locatelli F; Bertaina A; Bertaina V; Merli P
Expert Rev Hematol; 2016 Nov; 9(11):1093-1105. PubMed ID: 27690683
[TBL] [Abstract][Full Text] [Related]
17. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
Lemmermann NA; Reddehase MJ
Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus.
Pei XY; Zhao XY; Chang YJ; Liu J; Xu LP; Wang Y; Zhang XH; Han W; Chen YH; Huang XJ
J Infect Dis; 2017 Nov; 216(8):945-956. PubMed ID: 29029297
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.
Feuchtinger T; Opherk K; Bethge WA; Topp MS; Schuster FR; Weissinger EM; Mohty M; Or R; Maschan M; Schumm M; Hamprecht K; Handgretinger R; Lang P; Einsele H
Blood; 2010 Nov; 116(20):4360-7. PubMed ID: 20625005
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
Peggs KS; Mackinnon S
Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
